 Zealand Pharma AS - ADR NASDAQ: ZEAL shares are trading higher by 17.01 at 13.69 after the company announced the results from its phase 3 trial of Dasiglucagon in pediatric patients with congenital hyperinsulinism met the primary endpoint with statistical significance. Based on the trials. 